Patent · US Active

Biomarkers of response to NAE inhibitors

US9827246B2 · kind B2 · utility

3Cited by

3References

33Claims

0Family size

Assignee

Millennium Pharmaceuticals, Inc. · US

Inventors

Stephen J. Blakemore · Littleton, US
Bin Li · Columbus, US
George J. Mulligan · Lexington, US
Matthew C. Schu · Somerville, US
Peter Smith · Arlington, US

Key dates

Filing date	Oct 26, 2012
Grant date	Nov 28, 2017
Priority date	—
Expiry date	Oct 26, 2032

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A90/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.